In contrast to allogeneic bone marrow transplantation (allo-BMT), there is a paucity of data on cytomegalovirus (CMV) infection and pre-emptive therapy (PT) strategies following allogeneic peripheral blood stem cell (allo-PBSC) transplantation. We report here on the patterns of CMV infection in a cohort of 225 patients following sibling donor allo-PBSC transplantation. In an attempt to reduce neutropenia, we used intravenous low-dose shortcourse (LDSC) ganciclovir (GCV) 5 mg/kg once daily for 21 days as preemptive therapy. A total of 165 recipientdonor pairs were CMV seropositive. An initial episode of viremia (detected by shell vial/tube culture) occurred in 75/165 (45%) at a median of day þ 35 (17-445) post allo-PBSC. In all, 58 patients received PT with LDSC GCV. Among 58, 55 (94%) completed the 21-day course of PT. A second episode of viremia occurred in 19/58 (33%) at day þ 80 (50-174) and a third episode in 5/58 (9%) at day þ 134 (103-218). Among patients receiving LDSC GCV, 5/58(9%) developed disease (four pneumonia, one colitis) at day þ 211 . No patient on LDSC GCV exhibited a decline in their ANC below 500/ll and none required growth factors. LDSC GCV is extremely well tolerated and cost-effective as PT for CMV viremia following allo-PBSC transplantation.
clovir; pre-emptive therapy Cytomegalovirus (CMV) infection remains a major cause of morbidity and mortality following allogeneic transplantation. Before the common use of CMV-seronegative blood product support the incidence of CMV infection, following allogeneic bone marrow transplantation (allo-BMT), approached 70%. The introduction of filtered/CMV selected blood products decreased the incidence of CMV infection appreciably. 1, 2 Results were further improved with the use of prophylactic ganciclovir (GCV) from engraftment to day þ 100. 3, 4 However, with this approach clinically significant neutropenia was seen in up to 30% of treated patients. Neutropenia in allo-BMT recipients receiving GCV has been shown to be a negative predictor of overall and event-free survival. 5 The introduction of effective surveillance strategies made possible the use of pre-emptive therapy (PT) for CMV viremia. Initial reports that used monitoring with shell vial/tube culture administered intravenous GCV 5 mg/kg twice daily for 1-2 weeks (induction phase) followed by GCV once daily until day þ 100-120 post allo-BMT (maintenance phase). 6, 7 Unfortunately, this strategy was associated with a similar incidence of significant neutropenia. Subsequently, several investigators have attempted to use abbreviated regimens. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] However, all have included an induction phase of GCV 5 mg/kg twice daily for 1-2 weeks. Patients with evidence of persistent viremia received additional GCV 5 mg/kg once daily for a total of 21-28 days. Again, significant neutropenia was still seen in up to one-third of patients.
The literature on PT for prevention of CMV disease following allogeneic peripheral blood stem cell (allo-PBSC) transplantation is still limited to a few series with small numbers of patients. 10, [18] [19] [20] [21] In the absence of data, most institutions using GCV for PT therapy have adopted a regimen of GCV similar to that used in the allo-BMT setting. In an attempt to reduce the incidence of neutropenia, we have studied PT with intravenous low-dose shortcourse (LDSC) GCV 5 mg/kg once daily for 21 days in a large cohort of allo-PBSC recipients. We now report our results.
Patients and methods

Study population
A total of 225 patients underwent allo-PBSC from HLAidentical sibling donors at Washington University between September 1994 and April 2000. Details of patient characteristics, conditioning regimen and graft-versus-host disease (GVHD) prophylaxis employed and observed rates of acute GVHD are listed in Table 1 . Allo-PBSC products were infused without T-cell depletion. To avoid human error, all allo-PBSC recipients received CMV seronegative or filtered red cells and platelets, irrespective of the recipient's CMV serologic status. All patients received acyclovir for herpes simplex virus and trimethoprimsulfamethoxazole for Pneumocystis carinii prophylaxis till immunosuppression was discontinued. Of the allo-PBSC recipients with an ABO compatible allo-PBSC donor, 83 patients received HLA-matched G-CSF mobilized prophylactic granulocyte transfusions.
CMV monitoring
Recipients were routinely monitored for CMV viremia every 2 weeks (from engraftment to day þ 180). For rapid detection of CMV, shell vial cultures were performed on peripheral blood buffy coat specimen. 22, 23 In addition, conventional cultures were performed with specimens inoculated onto monolayers of human fibroblasts and maintained for 3 weeks. Monitoring for CMV viremia after day þ 180 was performed only if clinically indicated.
GCV therapy
PT with intravenous GCV 5 mg/kg once daily for 21 days was instituted following the initial detection of CMV viremia. Clearance of viremia was confirmed by a negative shell/vial tube culture within 1 week of completing a 21-day course of GCV. Shell vial/tube cultures for monitoring CMV during the 21-day course of GCV were performed at the discretion of the treating physician. Therapy for second and subsequent episodes of viremia was left to the discretion of the treating physician.
Definitions
CMV pneumonia was defined as the presence of interstitial infiltrates on chest radiograph accompanied by histologic demonstration of CMV on lung biopsy or a positive CMV culture on bronchoalveolar fluid. A diagnosis of CMV colitis was based on clinical and endoscopic signs of colitis, together with histologic demonstration of CMV inclusions or positive culture for CMV from tissue samples obtained at biopsy. Diagnosis and clinical grading of acute GVHD was performed according to established criteria. 24 
Results
CMV viremia
An initial episode of viremia occurred in 75/165 (45%) patients at risk for viremia at a median of 35 (17-445) days post allo-PBSC transplantation ( Table 2) . Out of 75 patients, 58 (77%) received therapy with LDSC GCV. The grades of GVHD in patients receiving LDSC GCV were Grade 0, 15 patients; Grade I, 13 patients; Grade II, 26 patients; Grade III-IV 4 patients. In all, 17 patients did not receive LDSC GCV due to a variety of reasons. Four patients had CMV disease at the time of the initial viremic episode and were given full treatment doses of therapy. Eight of the viremic patients were acutely ill and hospitalized with acute GVHD or other concurrent infection and were also given full treatment doses for therapy for their initial CMV viremia. Two patients who had negative shell vial cultures, but subsequently were reported to have CMV detected on conventional culture, did not receive any therapy for their CMV viremia. Two other patients were terminally ill with relapse of their disease at the time of the viremia and were provided comfort care only. One patient was treated with foscarnet secondary to a borderline neutrophil count at the time of the viremic episode. In all, 55 of the 58 (94%) patients completed 21 days of therapy with GCV. Therapy was stopped before day 21 in three patients. In one patient, therapy was changed to foscarnet on day 4 due to a decline in the ANC from 2600 to 750. Therapy for a second patient was changed to foscarnet by his treating physician when he failed to clear his viremia after 17 days on LDSC GCV. A third patient was admitted 14 days after detection of viremia with presumed sepsis and therapy was switched to GCV 5 mg/kg twice daily at that time. All three of these patients subsequently cleared their viremia. 
Results of PT
CMV disease
CMV disease was seen in 11/165 (7%) patients (nine pneumonia, two colitis) at a median 211 (41-855) days post allo-PBSC transplantation ( Table 2) . Five of the 58 (9%) patients receiving LDSC GCV developed CMV disease (four pneumonia, one colitis). No patient developed CMV disease while receiving LDSC GCV. Three of the 19 (15%) patients with recurrent viremia developed CMV disease. All patients who developed CMV disease early (od100) had active acute GVHD. Late CMV disease (4d100) was seen in 7/11 (64%) patients. Six of these seven patients developed CMV disease after day þ 180 post allo-PBSC transplantation, when routine surveillance for CMV viremia had been discontinued. All patients with late CMV disease had chronic GVHD and were receiving immunosuppressive therapy. Overall, 7/11 (64%) patients with CMV disease died. Four of the five (80%) patients who had received LDSC GCV as PT died of CMV disease. Among patients with recurrent viremia 1/19 (5%) died.
Toxicity
The median ANC prior to starting LDSC GCV was 6200/ ml (range 728-23500/ml). The median ANC on completion of a 21-day course of LDSC GCV was 3700/ml (range 740-14200/ml). Two of the 58 (3%) patients exhibited a decline in their ANC o1000/ml. One of these patients was taken off LDSC GCV and started on foscarnet on day 4 on account of a decline in the ANC from 2600/ml to 750/ml. No patients exhibited a decline in their ANC below 500/ml and none had to initiate growth factors for GCV-induced neutropenia.
Discussion
There are little published data on the incidence of CMV viremia following allo-PBSC transplantation. [18] [19] [20] [21] Theoretically, the use of peripheral blood as a source of stem cells for allografting could either increase or decrease the risk for CMV infection or disease when compared to bone marrow. Administration of greater numbers of leukocytes with peripheral blood from a seropositive donor could transmit a larger dose of virus increasing the likelihood of active infection. However, a greater number of immune effector cells contained in a peripheral blood allograft might afford the recipient greater protection from disease. Two published reports analyzing CMV viremia have reported a lower incidence of reactivation of CMV and a reduced risk of persisting CMV antigenemia following allo-PBSC transplantation. 18, 19 Others have found no difference or increase in viremia after allo-PBSC transplantation. 20, 21 To our knowledge, this report represents the largest published series on CMV infection following allo-PBSC transplantation. Although 83 of the allo-PBSC recipients in our series received HLA-matched G-CSF mobilized prophylactic granulocyte transfusions, we have previously reported that the infusion of granulocytes did not have an impact on the incidence of CMV viremia. 25 No IVIG was given either as general prophylaxis or in combination with LDSC GCV.
Of 165 patients, 75 (45%) at risk for CMV viremia had evidence of CMV reactivation by shell vial/tube culture after undergoing allo-PBSC transplantation. Previous large series looking at CMV viremia using shell vial/tube culture for CMV monitoring in the allo-BMT setting have reported similar rates of CMV viremia. 6, 26 We chose an every 2-week shell vial-based surveillance strategy for CMV. An earlier pilot study at our institution had shown that adopting the pp65 antigenemia assay offered no significant lead time advantage to shell vial in the detection of CMV viremia. 27 At the time this study was started in 1994, it was decided not to use a polymerase chain reaction (PCR)-based surveillance strategy as it was still being debated whether PCR was too sensitive a test for monitoring CMV viremia. It was thought by some that a PCR-based surveillance strategy may result in unnecessary exposure of several patients to the potential side effects of GCV. Also, at our institution a significant proportion of patients travel several hundred miles to be seen at the transplant center. As prolonged (180 days) weekly surveillance was not possible for all patients, it was decided to monitor for CMV viremia every 2 weeks.
Previous reports studying abbreviated regimens of intravenous GCV have used an induction phase (5 mg/kg twice daily) followed by maintenance therapy (5 mg/kg once daily) until clearance of viremia. Using antigenemia-based assays, 60-85% of patients have been reported to clear viremia after 2 weeks of therapy. 10, 12, 16, 19 When PCRbased surveillance strategies are employed, clearance rates of 37-50% have been reported after 2 weeks. 9, 11 In our series, 36/58 patients (62%) had negative shell vial cultures recorded on day 14 of LDSC GCV therapy. Due to the relatively small cohort of patients, it is not possible to establish any meaningful relationship between acute GVHD on response to therapy or progression to CMV disease. The rates of recurrent viremia employing abbreviated induction-maintenance regimens of GCV have been reported to vary between 13 and 63%. 8, [10] [11] [12] In our experience, recurrent viremia was detected in 19/58 (33%) receiving an initial course of LDSC GCV therapy. Clearly, our results using LDSC GCV compare favorably with those reported in the literature. In addition, a second course of LDSC GCV was successfully employed as PT in 9/19 (47%) cases where viremia recurred.
In our cohort of patients receiving PT with LDSC GCV, CMV disease was seen in 5/58 (9%) of patients. Among patients with recurrent viremia 3/19 (15%) of patients developed CMV disease. Once again, our results compare favorably with the 5-15% rate of CMV disease reported by previous studies looking at large series of patients treated with abbreviated courses of induction-maintenance therapy. 10, 11, 17 It is also important to note that none of our patients developed CMV disease while receiving LDSC GCV therapy. In the entire cohort of 165 patients at risk for CMV viremia, 11 patients developed CMV disease. Six of these 11 patients developed CMV disease after day þ 180 post allo-PBSC transplantation. All patients with late CMV disease (4d100) had chronic GVHD and were receiving immunosuppressive therapy. This is an important observation as the use of peripheral blood as a source of stem cells is increasing and several authors have reported a higher incidence of chronic GVHD following allo-PBSC transplantation when compared with allo-BMT. 28, 29 Our results suggest a need to continue routine surveillance for CMV viremia beyond day þ 180 following allo-PBSC transplantation, especially for patients receiving prolonged immunosuppression for chronic GVHD.
One of the salient features of our regimen using LDSC GCV as PT was the near absence of any significant hematologic toxicity. In our series using LDSC GCV only, 2/58 (3%) patients exhibiting a decline in their ANCo1000/ml. Only one of these two patients had LDSC GCV discontinued. This patient had a decline in the ANC from 2600/ml to 750/ml on day 4 of LDSC GCV therapy. The rapidity of the decline in the ANC makes it unlikely that it was related to the administration of GCV as GCVinduced neutropenia generally develops after a median of 18-21 days of therapy with GCV. 5, 14, 17 None of the patients in our cohort exhibited a decline in their ANC to o500/ml while on LDSC GCV and no patient required G-CSF support. Previous series using abbreviated inductionmaintenance schedules of GCV have reported a much higher incidence of neutropenia with about a third of patients developing an ANCo1000/ml and up to 20% of patients exhibited a decline in their ANC to o500/ml. [9] [10] [11] 13, 14, 16, 17 A substantial proportion of patients in these series also required growth-factor support that adds substantially to the overall cost of therapy. More importantly, Salzberger et al 5 have shown that neutropenia in patients receiving GCV is an independent risk factor for poor long-term outcome. In their series, a clear trend between the degree of neutropenia and rate of bacterial infections was observed. Neutropenia was an independent predictor for the overall survival and nonrelapse mortality.
In conclusion, LDSC GCV is an efficacious regimen for use as PT for CMV viremia in the allo-PBSC setting. The outcome of our strategy using shell vial/tube culture to monitor CMV viremia with LDSC GCV as PT in this large cohort of allo-PBSC recipients was equivalent to that reported by other authors using conventional induction-maintenance regimens of GCV as PT following allo-BMT. In contrast, the most remarkable feature in our series using LDSC GCV as PT was the near absence of any clinically significant hematological toxicity. PT with LDSC GCV provides a well-tolerated cost-effective and efficacious alternative to induction-maintenance regimens of GCV.
